HIKMA Pharmaceuticals PLC — Remuneration Information 2013

Mar 25, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8083A

Hikma Pharmaceuticals Plc

25 March 2013

Hikma Pharmaceuticals PLC - Vesting of 2010 LTIP

LONDON, 25 March 2013: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received conditional share awards which vested on 23 March 2013 under the 2005 Long Term Incentive Plan ("LTIP") and were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil. The persons concerned have retained all the shares exercised.

In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.

Bassam Kanaan	Vesting of LTIP 2010	49,476 (0.02% ISC)	25 March 2013		£10.24	Nil	468,134 (0.24% ISC)
Michael Raya	Vesting of LTIP 2010	44,384 (0.02% ISC)	25 March 2013		£10.24	Nil	56,584 (0.03% ISC)
Riad Mishlawi	Vesting of LTIP 2010	17,660 (0.01% ISC)	25 March 2013		£10.24	Nil	60,260 (0.03% ISC)
Khalid Nabilsi	Vesting of LTIP 2010	23,063 (0.01% ISC)	25 March 2013		£10.24	Nil	219,847 (0.11% ISC)

- ENDS -

Enquiries                                                                                                                                      

Peter Speirs                                                                          +44 20 7399 2760

Company Secretary, Hikma Pharmaceuticals PLC

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBSGDXGSDBGXU